Literature DB >> 7531540

Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the alpha-galactosidase A gene.

C M Eng1, D J Niehaus, A L Enriquez, T S Burgert, M D Ludman, R J Desnick.   

Abstract

Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the alpha-galactosidase A gene at Xq22.1. To determine the nature and frequency of the molecular lesions causing the classical and milder variant Fabry phenotypes, and for precise carrier detection in Fabry families, the alpha-galactosidase A coding and flanking intronic sequences from 23 unrelated Fabry hemizygotes were analyzed. In patients with the classic phenotype, 16 new missense and nonsense mutations and four small exonic gene rearrangements were identified: C52S, C56F, E59K, L89R, R100K, R112H, L131P, A143P, G144V, C172Y, D244N, N272K, A288D, W81X, Q99X, Q157X, R301X, 25del1, 333del18, 358del6, and 1020del1. The R112H mutation at a CpG dinucleotide resulted in residual activity and a mild variant phenotype while the R112C lesion caused the classic disease manifestations, defining a genotype/phenotype correlation for sense and antisense mutations at the same CpG dinucleotide. In addition, two complex rearrangements, each involving two mutational events, occurred in classic hemizygotes. Both rearrangements resulted in missense mutations that did not change the reading frame. Notably, three of the deletions occurred within 11 codons in exon 2, thereby defining a 'hot-spot' for deletions. These studies revealed that most mutations in the alpha-galactosidase A gene causing Fabry disease were private, that codons 111-122 defined a deletion hot-spot, and that different substitutions of the same codon resulted in markedly different disease phenotypes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7531540     DOI: 10.1093/hmg/3.10.1795

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  41 in total

1.  Human alpha-galactosidase A: high plasma activity expressed by the -30G-->A allele.

Authors:  T F Fitzmaurice; R J Desnick; D F Bishop
Journal:  J Inherit Metab Dis       Date:  1997-09       Impact factor: 4.982

Review 2.  Renal pathological changes in Fabry disease.

Authors:  A Sessa; M Meroni; G Battini; A Maglio; P L Brambilla; M Bertella; M Nebuloni; F Pallotti; F Giordano; B Bertagnolio; A Tosoni
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene.

Authors:  I Redonnet-Vernhet; J K Ploos van Amstel; R P Jansen; R A Wevers; R Salvayre; T Levade
Journal:  J Med Genet       Date:  1996-08       Impact factor: 6.318

4.  Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes.

Authors:  C M Eng; G A Ashley; T S Burgert; A L Enriquez; M D'Souza; R J Desnick
Journal:  Mol Med       Date:  1997-03       Impact factor: 6.354

5.  A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted.

Authors:  N Miyamura; E Araki; K Matsuda; R Yoshimura; N Furukawa; K Tsuruzoe; T Shirotani; H Kishikawa; K Yamaguchi; M Shichiri
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

6.  Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.

Authors:  Caterina Porto; Antonio Pisani; Margherita Rosa; Emma Acampora; Valeria Avolio; Maria Rosaria Tuzzi; Bianca Visciano; Cristina Gagliardo; Serena Materazzi; Giancarlo la Marca; Generoso Andria; Giancarlo Parenti
Journal:  J Inherit Metab Dis       Date:  2011-12-21       Impact factor: 4.982

7.  Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility.

Authors:  Y A Ioannou; K M Zeidner; M E Grace; R J Desnick
Journal:  Biochem J       Date:  1998-06-15       Impact factor: 3.857

8.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Authors:  Johannes M Aerts; Johanna E Groener; Sijmen Kuiper; Wilma E Donker-Koopman; Anneke Strijland; Roelof Ottenhoff; Cindy van Roomen; Mina Mirzaian; Frits A Wijburg; Gabor E Linthorst; Anouk C Vedder; Saskia M Rombach; Josanne Cox-Brinkman; Pentti Somerharju; Rolf G Boot; Carla E Hollak; Roscoe O Brady; Ben J Poorthuis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Agalsidase alfa and kidney dysfunction in Fabry disease.

Authors:  Michael West; Kathy Nicholls; Atul Mehta; Joe T R Clarke; Robert Steiner; Michael Beck; Bruce A Barshop; William Rhead; Robert Mensah; Markus Ries; Raphael Schiffmann
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

10.  Structure-function relationships in alpha-galactosidase A.

Authors:  Scott C Garman
Journal:  Acta Paediatr       Date:  2007-04       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.